Clinical Scorecard: Evaluation of Peer Referral Strategies and Outcomes at 6 Months in a Digital Weight Loss Program Utilizing Tirzepatide: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• Referred patients showed higher medication adherence (48%) compared to nonreferred patients (42%) at 6 months.

• Mean weight loss was significantly greater in referred patients (16.2%) than in nonreferred patients (14.1%).

• The study included a total of 34,449 patients, with 2,576 referred and 31,873 nonreferred.

• Peer referral may enhance accountability and social proof in weight loss interventions.

• Adherence was operationally defined by medication orders and weight entry submissions.

Guideline-Based Recommendations

Diagnosis

• The study population consisted of adults with obesity who initiated tirzepatide treatment in a digital weight-loss program.

Management

• Utilize peer referral strategies to improve adherence in digital weight-loss programs.

Monitoring & Follow-up

• Track medication orders and weight entries to assess adherence and outcomes.

Risks

• As a retrospective cohort analysis, the study cannot establish that peer referral caused differences in adherence or weight loss.

• Findings may not generalize beyond adults initiating tirzepatide in digital weight-loss services.

Patient & Prescribing Data

Adults with obesity initiating tirzepatide treatment

Adherence to medication and behavioral modification are critical for effectiveness.

Clinical Best Practices

• Implement peer referral systems to enhance patient engagement and retention.

• Monitor patient adherence through regular tracking of medication orders and weight data.

Related Resources & Content

1. Aronne LJ, Sattar N, Horn DB, et al., JAMA, 2024 -- Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.

2. Hankosky ER, Chinthammit C, Meeks A, et al., Diabetes Obes Metab, 2025 -- Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes.

3. Talay L, Hom J, Scott T, Ahuja N, Diabetes Obes Metab, 2026 -- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia.

4. the new gastroenterologist — Tirzepatide outperforms semaglutide for weight loss

5. MDSpire News — How Hormones May Influence Tirzepatide Outcomes

6. FDA Approves New Medication for Chronic Weight Management

7. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026

8. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity | Diabetes, Obesity, and Cardiometabolic CARE | American Diabetes Association

9. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update - Endocrine Practice

10. Practice guide on obesity, weight management, education, and resources - American Gastroenterological Association

11. Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

12. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial - PMC

13. Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies - Paccola - 2026 - Clinical Obesity - Wiley Online Library

14. Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population | Journal of Managed Care & Specialty Pharmacy

15. Journal of Medical Internet Research - Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service